CD8A and ovarian carcinoma: Recent findings demonstrate that Cyst(e)inase treatment in combination with anti-PD-L1 checkpoint blockade synergistically enhanced T cell-mediated anti-tumor immunity, elevating tumoral lipid ROS and increasing populations of IFNγ/TNF expressing CD8 + /CD4 + T cells in an ovarian cancer model [21].